News & Updates

Show Multimedia Only

More complications, readmissions seen in RCC patients with comorbidities

08 Jul 2026

Renal cell carcinoma (RCC) patients with comorbidities are at greater risk for postoperative kidney and urinary complications and readmissions, reports a study, noting the importance of comorbidity management in surgical care in this population.

More complications, readmissions seen in RCC patients with comorbidities

08 Jul 2026

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

08 Jul 2026 by

In the phase III MonumenTAL-3 trial, talquetamab plus daratumumab (Tal-D), with or without pomalidomide, shows substantial efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM), compared with daratumumab, pomalidomide, and dexamethasone (DPd).

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

08 Jul 2026

Consistent resistance training, limited sedentary behaviour help lower T2D risk

08 Jul 2026

Engaging in resistance training over midlife and limiting sedentary behaviour have been shown to substantially lower the risk of type 2 diabetes (T2D) in a study.

Consistent resistance training, limited sedentary behaviour help lower T2D risk

08 Jul 2026

Selinexor-ruxolitinib combo improves SVR in patients with JAKi-naïve myelofibrosis

08 Jul 2026 by

In patients with Janus kinase inhibitor (JAKi)-naïve myelofibrosis, the addition of selinexor to ruxolitinib significantly improves the incidence of spleen volume reduction of ≥35 percent (SVR35) compared with ruxolitinib alone, according to the SENTRY trial presented at ASCO 2026.

Selinexor-ruxolitinib combo improves SVR in patients with JAKi-naïve myelofibrosis

08 Jul 2026

Triple win for fixed-dose combo in T2D

08 Jul 2026 by

A fixed-dose combination of the novel amylin receptor agonist cagrilintide and the approved GLP-1 receptor agonist semaglutide (CagriSema) yields better HbA_1c control and weight loss in patients with type 2 diabetes (T2D) than either therapy alone or placebo in three phase III trials from the global REIMAGINE programme presented at ADA 2026. The benefits also extend to patients on insulin therapy.

Triple win for fixed-dose combo in T2D

08 Jul 2026

No clear link between prenatal acid suppressant use and IBD in offspring

07 Jul 2026

In vitro exposure to acid-suppressive medications does not appear to be associated with an increased risk of inflammatory bowel disease (IBD) development in offspring, as shown in a nationwide cohort study.

No clear link between prenatal acid suppressant use and IBD in offspring

07 Jul 2026

Low vision-threatening DR incidence contrasts with high progression rate among Asians

07 Jul 2026 by

The overall development of vision-threatening diabetic retinopathy (DR) among Asians with diabetes is low, although the incidence of progression to vision-threatening disease for those who already have DR is high, according to local research.

Low vision-threatening DR incidence contrasts with high progression rate among Asians

07 Jul 2026

Comorbidities delay RT in patients with brain tumours

07 Jul 2026

Patients with malignant brain tumours and several comorbidities tend to have delayed radiotherapy (RT), reveals a study.

Comorbidities delay RT in patients with brain tumours

07 Jul 2026

Efgartigimod improves platelet response in primary ITP

07 Jul 2026 by

The use of efgartigimod in adult patients with primary immune thrombocytopenia (ITP) results in higher platelet response with no increase in serious adverse events (AEs), reports a meta-analysis of phase III randomized controlled trials (RCTs).

Efgartigimod improves platelet response in primary ITP

07 Jul 2026

MELD best predictor of outcomes in alcohol-related liver disease: study

07 Jul 2026

A recent study describes the natural history of alcohol-associated liver disease (ALD) and the risks of outcomes based on the model for end-stage liver disease (MELD) score across the ALD spectrum.

MELD best predictor of outcomes in alcohol-related liver disease: study

07 Jul 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

More complications, readmissions seen in RCC patients with comorbidities

More complications, readmissions seen in RCC patients with comorbidities

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

Consistent resistance training, limited sedentary behaviour help lower T2D risk

Consistent resistance training, limited sedentary behaviour help lower T2D risk

Selinexor-ruxolitinib combo improves SVR in patients with JAKi-naïve myelofibrosis

Selinexor-ruxolitinib combo improves SVR in patients with JAKi-naïve myelofibrosis

Triple win for fixed-dose combo in T2D

Triple win for fixed-dose combo in T2D

No clear link between prenatal acid suppressant use and IBD in offspring

No clear link between prenatal acid suppressant use and IBD in offspring

Low vision-threatening DR incidence contrasts with high progression rate among Asians

Low vision-threatening DR incidence contrasts with high progression rate among Asians

Comorbidities delay RT in patients with brain tumours

Comorbidities delay RT in patients with brain tumours

Efgartigimod improves platelet response in primary ITP

Efgartigimod improves platelet response in primary ITP

MELD best predictor of outcomes in alcohol-related liver disease: study

MELD best predictor of outcomes in alcohol-related liver disease: study